A Data Resource for Analyzing Blood and Marrow Transplants

项目摘要/摘要 国际血液和骨髓移植研究中心(CIBMTR)是一个临床研究项目 致力于解决造血细胞移植(HCT)领域的重要问题。CIBMTR 维护一个大型结果注册表，其中包含&gt；420个中心的475,000名HCT接受者的信息，并提供 为分析这些数据提供统计支持。一个单独资助的捐赠者-接受者研究库 链接到这些临床数据的样本可供大部分患者使用，生成的数据也是如此 对这些标本的分析，包括高分辨率人类白细胞抗原(HL A)数据和 基因组测序。世界各地数以千计的研究人员在当前的 以前的供资周期为1100份关于重要问题的出版物做出了贡献，改善了全球 在数据交换和HCT研究方面进行合作，并增加供应商可获得的数据量 和患者的临床决策。随着U24-CA76518的更新，CIBMTR将继续在 基础设施，以促进深入探索临床、免疫学、遗传学、 生活质量，以及与HCT有关的卫生服务问题。此应用程序建议增强此资源 并通过以下具体目标提高其效用： 资源开发：维护和加强CIBMTR高质量的临床数据库和最先进的 提供统计支持，通过持续发展，解决人类安全技术及相关领域的重要问题 最先进的数据收集、管理和共享技术和程序，扩展 基础设施，以获取患者报告的结果和细胞疗法，开发和应用 新的统计技术，以及与国家和国际网络在艾滋病毒和相关领域的合作 菲尔兹。 资源利用率：增加对CIBMTR维护的数据和统计资源的使用，以支持 研究具有重要临床和政策意义的恶性和非恶性疾病，并加强 确定和完成这些研究的优先次序的程序。

PROJECT SUMMARY/ABSTRACT The Center for International Blood and Marrow Transplant Research (CIBMTR) is a clinical research program dedicated to addressing important issues in the field of hematopoietic cell transplantation (HCT). CIBMTR maintains a large outcomes registry with information for >475,000 HCT recipients in >420 centers and provides statistical support for analyzing those data. A separately funded Research Repository of donor-recipient specimens linked to these clinical data is available for a large subset of patients, as are data generated from analyses of these specimens, including high-resolution human leukocyte antigen (HLA) data and whole genome sequencing. Use of this Resource by thousands of investigators around the world during the current and previous funding cycles have contributed to >1,100 publications on important issues, to improved global collaboration in data exchange and HCT research and to increase the amount of data available to providers and patients for clinical decision-making. With renewal of U24-CA76518, CIBMTR will continue to build on the infrastructure made possible by this support to facilitate in-depth exploration of clinical, immunologic, genetic, quality of life, and health services issues related to HCT. This application proposes to enhance this Resource and to advance its utility through the following Specific Aims: Resource Development: Maintain and enhance CIBMTR’s high-quality clinical database and state-of-the-art statistical support to address important issues in HCT and related fields through continued development of state-of-the-art data collection, management and sharing technologies and procedures, expansion of infrastructure to capture patient-reported outcomes and cellular therapies, development and application of novel statistical techniques, and collaboration with national and international networks in HCT and related fields. Resource Utilization: Increase use of data and statistical resources maintained by the CIBMTR to support studies in malignant and non-malignant diseases with important clinical and policy implications, and enhance processes to prioritize and complete these studies.